Inovio Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Inovio Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Self-Funding Ratio: Over the last 3 years operating cash was negative while the company kept spending on investment (capex). Lower than 93% of Healthcare companies in United States.
Where $100 of sales goes
Latest year (Dec 2025). Taxes and other income are not shown, so the parts need not add up to 100.
Cash quality
Profit Cash Ratio
—Loss-making or profit too small
Over the last 3 years profit was a loss or under 2% of sales, so cash per 100 of profit is not meaningful.
Self-Funding Ratio
-289.7×Over the last 3 years operating cash was negative while the company kept spending on investment (capex).
Lower than 93% of Healthcare companies in United States.
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 3/3Sales grew in 0 of the last 3 years; profit grew in 3 of 3.
Steadier than 50% of Healthcare companies in United States.
Growth Efficiency Ratio
—Sales fell 99%
Sales fell 99% in 3 years, so extra profit per extra sales cannot be measured.
Asset Productivity Ratio
-99% / -79%In 3 years sales changed by -99% while total assets changed by -79%. Assets grew faster than sales.
Balance-sheet strength
Debt Due Cover Ratio
-31.4×Operating cash was negative last year, while some debt falls due within a year.
Lower than 64% of Healthcare companies in United States.
Cash Cushion Ratio
+57%Cash, after subtracting all debt, equals 57% of its market value (net cash).
Higher than 79% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (12)
Inovio Pharmaceuticals, Inc. made a loss over the last year. Inovio Pharmaceuticals, Inc. owes $0.91 for every $1 it owns. Inovio Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossInovio Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
19.84The share price is 19.84 times Inovio Pharmaceuticals, Inc.'s book value per share, higher than 94% of Healthcare companies in United States.
Market cap
$87 MThe total market value of all of Inovio Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 68% of Healthcare companies in United States. PosiCap size class: Micro Cap.
Net worth (book value)
$4 MWhat Inovio Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$0.04Net worth divided by the number of shares. The share price of $0.84 is 19.8 times this, which is the P/B above.
Return on equity (ROE)
-409.9%Inovio Pharmaceuticals, Inc. lost 409.9% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
Owes vs Owns
0.91×Inovio Pharmaceuticals, Inc. owes $0.91 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Dividend yield
NoneInovio Pharmaceuticals, Inc. does not currently pay a dividend.
Revenue growth
-70%Revenue fell 70% in the year to Dec 2025, and shrank 81% a year on average over 3 years.
Profit growth
LossInovio Pharmaceuticals, Inc. made a loss in each of the last two years.
Profit margin
-130000.0%Inovio Pharmaceuticals, Inc. lost $130000 for every $100 of revenue.
Cash vs debt
Net cashInovio Pharmaceuticals, Inc. held $49 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Inovio Pharmaceuticals, Inc.: $87 M ÷ $4 M (30 Jun 2026) = 19.8.
What is Inovio Pharmaceuticals, Inc.'s return on equity?
Inovio Pharmaceuticals, Inc. lost 409.9% of its shareholders' money over the last year, lower than 92% of Healthcare companies in United States.
How much does Inovio Pharmaceuticals, Inc. owe compared with what it owns?
Inovio Pharmaceuticals, Inc. owes $0.91 for every $1 it owns (high), higher than 83% of Healthcare companies in United States.
Does Inovio Pharmaceuticals, Inc. pay a dividend?
No. Inovio Pharmaceuticals, Inc. does not currently pay a dividend.
Is Inovio Pharmaceuticals, Inc.'s revenue growing?
Revenue fell 70% in the year to Dec 2025, and shrank 81% a year on average over 3 years.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.